PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.
days to go:
Expired
investment:
£49,990
Doctaly is the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go:
Expired
investment:
£807,580
Offering a more affordable fitness class solution through training small groups and providing unparalleled client care with 1-on-1 personal training sessions. Outrivals has grown rapidly since launching 3 years ago near the famous Old Street Roundabout and are raising funds to open 2 new sites, with plans to have a portfolio of 15 branches over the next 5 years. The company has a high retention rate, with a client life cycle averaging one year.
days to go:
Expired
investment:
£88,450
Rabble is a gamified and licensed fitness program that transforms exercise into fun, team-based games. It was first formed by a former international athlete and then financed by investors from the LA Fitness & Liverpool football club. Rabble has quickly risen to 100 authorized sites strengthening many healthy communities over the UK. It is a differentiated concept which is named as Global Fitness Trend (WGSN). It has a proven and scalable model where the market leaders earn revenue of more than $100m. Further, it has developed 100+ instructors across the UK in less than one year. Rabble aims at helping and changing more lives with the finance that it raises. It is planning to grow to more than 300 Rabble sites in the coming year.
days to go:
Expired
investment:
£274,530
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.
days to go:
Expired
investment:
£290,278
Centaur Robotics is redefining mobility for the 10% of the global population who require assistance to walk 400 meters. Representing a £7 billion global opportunity, the company offers a blend of convenient service and innovative two-wheeled vehicle design, catering to individuals and collaborating with international brands in sectors such as airlines, shopping centers, retirement living, hotels, and restaurants.
After a successful 2020 investment round, Centaur Robotics is currently seeking the final £65,000 of its seed equity round. This funding will facilitate pre-production market trials, design refinements, large-scale testing, and production expansion. With established commercial traction, the company aims for a full commercial launch by June 2024.
days to go:
Expired
investment:
£795,101
Vegums develop multivitamin gummies for a vegan and plant-based lifestyle. The company argues that some vitamins are difficult to get from a plant-only diet, such as vitamin D, B12, and iodine. Vegums has researched and incorporated non-animal vitamin ingredients into its products to address that issue. The company asserts that its products are 100% plastic-free and biodegradable. It claims that the number of vegans in the UK grew by 40% in 2020, and shows no sign of slowing down in 2021. It aims to become a contender in this segment. Vegums won the World Plant Award 2020 for the 'Best Plant-Based Start-Up', has a social media following of over 15,700 on Instagram, achieved 4.8/5 on TrustPilot, and scaled from selling 1 pack of Vegums to over 9,000 a month to its customers. It will use the investment for New Product Development (NPD), team expansion, and launching into new markets and countries.
days to go:
Expired
investment:
£312,463
